Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx31x2.htm |
| EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx31x1.htm |
| EX-23.1 - EXHIBIT 23.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx23x1.htm |
| EX-21.1 - EXHIBIT 21.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx21x1.htm |
| EX-12.1 - EXHIBIT 12.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx12x1.htm |
| EX-10.21 - EXHIBIT 10.21 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10-21.htm |
| EX-10.8 - EXHIBIT 10.8 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10-8.htm |
| EX-10.2.1 - EXHIBIT 10.2.1 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10x2x1.htm |
| 10-K - 10-K - INTERCEPT PHARMACEUTICALS, INC. | v485049_10k.htm |
Exhibit 32
CERTIFICATIONS UNDER SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intercept Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2017 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
 |
|
|
| Dated: February 28, 2018 | /s/ Mark Pruzanski Mark Pruzanski, M.D. President and Chief Executive Officer (Principal Executive Officer) |
|
| Dated: February 28, 2018 | /s/ Sandip Kapadia Sandip Kapadia Chief Financial Officer (Principal Financial and Accounting Officer) |